Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
August 22, 2024 04:27 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All...
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
July 29, 2024 07:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
July 23, 2024 19:49 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA)...
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
July 17, 2024 19:14 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the...
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
July 10, 2024 21:40 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare &...
Telix Announces Launch of Proposed Initial Public Offering in the United States
June 05, 2024 07:29 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the...
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
June 02, 2024 18:43 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License...
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
May 30, 2024 18:49 ET
|
Telix Pharmaceuticals Limited
TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported median...
Telix Submits NDA for New Prostate Cancer Imaging Agent
May 28, 2024 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States...
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
May 20, 2024 19:46 ET
|
Telix Pharmaceuticals Limited
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix’s proprietary RADmAb®...